Myasthenia Gravis Treatment Market

Myasthenia Gravis Treatment Market by Treatments (Medication, Surgery, and Others), End-Users (Hospitals, Clinics, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1822
  • Author: Growth Market Reports
  • Rating: 4.7
  • Total Reviews: 3
  • No. Of Pages: 177
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global myasthenia gravis treatment market size is projected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the growing adoption of rare diseases, approvals for promising drugs, increasing adoption of immunotherapies, and emergence of biologics.

Myasthenia Gravis Treatment Market Key Takeaways

Myasthenia gravis (MG) is rare, chronic, and progressive neuromuscular disorder which causes weakness of the head, eye, limb, respiratory muscles, and spinal. MG is autoimmune disorder in which against the acetylcholine receptor (AchR) antibodies are produced. Myasthenia gravis hampers the normal transmission of electrical signals from nerves to muscles.

According to the National Organization for Rare Disorders (NORD), approximately 20-35 per 100,000 individuals suffer from myasthenia gravis in the U.S. also, number of disorders are increasing over the last several decades. This is attributed to rising incidence of autoimmune disorders and better identification of patients across the globe.

Myasthenia gravis occurs generally in females than in males. Symptoms of MG appears at any age, but in men it’s appear during their 50s or 60s and in women usually in their 20s or 30s. There is no permanent cure for myasthenia gravis disease. But there are some treatments such as medications and surgery for slows down the disease progression, management of the symptoms, and prevention of unnecessary complications. Currently, researchers are majorly focused on understanding the specifics of the autoimmune problems related to MG and improving diagnosis methods and treatments. Moreover, other important area of research physiology of the neuromuscular junction (NMJ), is improving its function irrespective of probable immune system attacks.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing research and development activities and growing number of clinical trials for treatment are anticipated to drive the market growth over the forecast period.
  • Rising population with MG disease in emerging countries, growing geriatric population, and increasing cases of neuromuscular disorders are expected to boost the growth of the market.
  • Increasing awareness about the treatment line among patients and growing number of clinical facilities are projected to propel the market growth.
  • Side effects of drugs, high cost of treatment, and high dose combination results into severe muscle cramps are major factors that can impede the market growth.
  • In Covid-19 pandemic situation researchers are focusing on Covid-19 research. Due to this other clinical trials and researches are reduced which hampered the growth of myasthenia gravis treatment market.

Scope of the Report

The report on the global myasthenia gravis treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Myasthenia Gravis Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Treatments (Medication, Surgery, and Others), End-Users (Hospitals, Clinics, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc., Novartis AG, Pfizer Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Bausch Health Companies Inc., and Shire plc.

Market Segment Insights

Medication segment is projected to hold a key market share

Based on treatments, the myasthenia gravis treatment market is divided into medication, surgery, and others. The medication segment is expected to hold a key share of the market during the forecast period. This is due to medications are dramatically constrain the immune system and majorly manages the associated symptoms. Medications include immunotherapies such as corticosteroids, Soliris (eculizumab), and immunosuppressive drugs includes Neoral/Sandimmune (cyclosporine) and Prograf (tacrolimus).

Surgery is other major treatment alternative which includes a thymectomy (thymus removal). It is invasive in nature. The thymus deteriorates with age (thymic involution), though complete loss of the thymus in a significant manner is expected to weaken a patient’s immune system.

Increasing number of pipeline R&D of drug development is projected to fuel the growth of the myasthenia gravis treatment market. Recently, the U.S. FDA and the European Commission, approved Alexion Pharmaceuticals’ Soliris (eculizumab) for treating adult myasthenia gravis patients who are anti-AchR antibody-positive. Soliris is a complement and first inhibitor for this disorder. The rising use of immunosuppressant and monoclonal antibodies is targeted the reduction of lifelong exposure to corticosteroids.

Myasthenia Gravis Treatment Market By Treatments

Clinic segment is expected to expand at a rapid pace

On the basis of end-users, the myasthenia gravis treatment market is segmented into hospitals, clinics, and others. The hospital segment is expected to hold a key share of the market during the forecast period. The growth of the segment is attributed to high demand of advanced equipment for myasthenia gravis treatment and huge patient pool. Number of patient visits for the MG treatment is increasing because of accessibility of such facilities. Moreover, rising investment in state-of-the-art healthcare infrastructures is one of the major driving factor.

On the other hand, the clinic segment is anticipated to expand at a rapid pace during the forecast period. Recently, need of specialized treatments is increasing also many patients are choosing specialty clinics for effective treatment and quick diagnosis. Furthermore, many end-users are dependent on e-commerce channel for treatment. Such segments are majorly boosting the growth of myasthenia gravis treatment market.

North America is anticipated to dominate the market

On the basis of regions, the myasthenia gravis treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America hold largest market share and is expected to exhibit a rapid growth rate in the coming years. The regional market growth can be attributed to growing expenditure on healthcare, huge adoption of immunotherapies and monoclonal antibodies, favorable reimbursement scenario, and presence of established R&D facilities.

However, the market of Asia Pacific is anticipated to expand at an impressive CAGR during the forecast period owing to the growing generation of revenue through medications such as immunosuppressant and monoclonal antibodies in this region. Furthermore, initiatives taken by government and manufacturers for increasing investment is one of the boosting factor responsible for the regional growth.

Myasthenia Gravis Treatment Market By Regions

Segments

Segments Covered in the Report
The global myasthenia gravis treatment market has been segmented on the basis of

Treatments
  • Medication
  • Surgery
  • Others
End-Users
  • Hospitals
  • Clinics
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Alexion Pharmaceutical Inc.
  • Grifols SA
  • Avadel Pharmaceuticals plc.
  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc.
  • Bausch Health Companies Inc.
  • Shire plc.

Competitive Landscape

Key players competing in the myasthenia gravis treatment market are Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc., Novartis AG, Pfizer Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Bausch Health Companies Inc., and Shire plc.

Many key players are launching new products and constant innovation are driving the market growth. For instance, Argenx, in June 2020, introduced its awareness efforts for autoimmune disease myasthenia gravis. Also, major market players implement several other business strategies such as mergers, acquisitions, partnerships, collaborations, and capacity expansion to enhance their market shares.

Myasthenia Gravis Treatment Market By Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Myasthenia Gravis Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Myasthenia Gravis Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Myasthenia Gravis Treatment Market - Supply Chain
  4.5. Global Myasthenia Gravis Treatment Market Forecast
     4.5.1. Myasthenia Gravis Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Myasthenia Gravis Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Myasthenia Gravis Treatment Market Absolute $ Opportunity
5. Global Myasthenia Gravis Treatment Market Analysis and Forecast by End Users
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by End Users
     5.2.2. Y-o-Y Growth Projections by End Users
  5.3. Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
     5.3.1. Hospitals Clinics Others
  5.4. Absolute $ Opportunity Assessment by End Users
  5.5. Market Attractiveness/Growth Potential Analysis by End Users
6. Global Myasthenia Gravis Treatment Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Myasthenia Gravis Treatment Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
7. North America Myasthenia Gravis Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
     7.4.1. Hospitals Clinics Others
  7.5. Basis Point Share (BPS) Analysis by End Users
  7.6. Y-o-Y Growth Projections by End Users
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
8. Latin America Myasthenia Gravis Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
     8.4.1. Hospitals Clinics Others
  8.5. Basis Point Share (BPS) Analysis by End Users
  8.6. Y-o-Y Growth Projections by End Users
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
9. Europe Myasthenia Gravis Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
     9.4.1. Hospitals Clinics Others
  9.5. Basis Point Share (BPS) Analysis by End Users
  9.6. Y-o-Y Growth Projections by End Users
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Myasthenia Gravis Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
     10.4.1. Hospitals Clinics Others
  10.5. Basis Point Share (BPS) Analysis by End Users
  10.6. Y-o-Y Growth Projections by End Users
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Myasthenia Gravis Treatment Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
     11.4.1. Hospitals Clinics Others
  11.5. Basis Point Share (BPS) Analysis by End Users
  11.6. Y-o-Y Growth Projections by End Users
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Myasthenia Gravis Treatment Market: Market Share Analysis
  12.2. Myasthenia Gravis Treatment Distributors and Customers
  12.3. Myasthenia Gravis Treatment Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Alexion Pharmaceutical Inc. Grifols SA Avadel Pharmaceuticals plc. Novartis AG Pfizer Inc. AbbVie Inc.
Segments Covered in the Report
The global myasthenia gravis treatment market has been segmented on the basis of

Treatments
  • Medication
  • Surgery
  • Others
End-Users
  • Hospitals
  • Clinics
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Alexion Pharmaceutical Inc.
  • Grifols SA
  • Avadel Pharmaceuticals plc.
  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc.
  • Bausch Health Companies Inc.
  • Shire plc.

Key players competing in the myasthenia gravis treatment market are Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc., Novartis AG, Pfizer Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Bausch Health Companies Inc., and Shire plc.

Many key players are launching new products and constant innovation are driving the market growth. For instance, Argenx, in June 2020, introduced its awareness efforts for autoimmune disease myasthenia gravis. Also, major market players implement several other business strategies such as mergers, acquisitions, partnerships, collaborations, and capacity expansion to enhance their market shares.

Myasthenia Gravis Treatment Market By Key Players

Buy Report